Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier, Mark Stevenson, David Hoffmeister, Tony White, Michael Egholm, Jason Affourtit, Brian Desany, David Bentley, Sean Humphray, Tony Cox, Scott Kahn, Keira Cheetham, Francisco De La Vega, Clarence Lee, Gina Costa, Kevin McKernan, Fiona Hyland, He

Premium
Greg Lucier, chairman, president, and CEO of Invitrogen, will become CEO of Applied Biosystems following Invitrogen’s planned acquisition of the company.  
 
Mark Stevenson, president and chief operating officer of ABI, will retain that role in the new company.
 
David Hoffmeister, senior vice president of finance and chief financial officer of Invitrogen, will remain CFO of the new ABI.
 
Tony White, chairman, president, and CEO of ABI’s parent Applera, will become an unpaid consultant to the new company for a period of five years.
 

 
Representatives from 454 Life Sciences, Illumina, and Applied Biosystems have joined a variety of committees and groups of the 1000 Genomes Project after their companies said they would participate in it.
 
For 454 Life Sciences, Michael Egholm, vice president of R&D, has joined the steering committee, the samples and ELSI group, and the production group; Jason Affourtit, group leader for advanced technologies integration, and Brian Desany, a senior bioinformatics scientist, have become members of the production group, the analysis group, and the data flow group.
 
For Illumina, Chief Scientist David Bentley has become a member of the steering committee; Sean Humphray, manager of scientific research, has joined the samples and ELSI group, the production group, the analysis group, and the data flow group; senior scientist Tony Cox and vice president and chief information officer Scott Kahn have joined the analysis group and the data flow group; and scientist Keira Cheetham has become a member of the analysis group.
 
For ABI, Francisco De La Vega, vice president for SOLiD system applications and bioinformatics, has joined the steering committee, the production group, the analysis group, and the data flow group; Clarence Lee, an R&D senior scientist, has joined the samples and ELSI group; Gina Costa, director of R&D projects, and Kevin McKernan, senior director for scientific operations, have become members of the production group; Fiona Hyland and Heather Peckham, both R&D staff scientists for bioinformatics, have joined the analysis group; and Tim Hunkapiller, a consultant to ABI, has become a member of the data flow group.
 

 
Gunther Stent died at age 84. He was chairman of the department of molecular biology at the University of California, Berkeley, from 1980 to 1986. Earlier, he was an associate of Max Delbrück at the California Institute of Technology, studying bacteriophages. As part of his research, Stent helped to validate the double helix structure of DNA. Born in Germany, he emigrated to the US during the Nazi regime, where he obtained a bachelor’s degree and a PhD in chemistry from the University of Illinois.
 

 
Ratan Tata and Michael Boustridge have joined the board of trustees of the X Prize Foundation. Tata is the chairman of Tata Sons, the holding company of the Tata Group of India. He holds a BS in architecture from Cornell University. Boustridge is the president of BT Americas, one of four regions of BT Global Services.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.